scholarly journals Treatment of Exudative Age-Related Macular Degeneration with Intravitreal Ranibizumab in Clinical Practice: A 3-Year Follow-Up

2013 ◽  
Vol 229 (3) ◽  
pp. 158-167 ◽  
Author(s):  
Inês P. Marques ◽  
Pedro Fonseca ◽  
M. Luz Cachulo ◽  
Isabel Pires ◽  
João Figueira ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

Comparison of the Effectiveness and Prognostic Factors of Intravitreal Ranibizumab between Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy over 24 Months of Follow-Up

2015 ◽  
Vol 234 (1) ◽  
pp. 33-39 ◽  
Author(s):  
Wataru Matsumiya ◽  
Shigeru Honda ◽  
Keiko Otsuka ◽  
Akiko Miki ◽  
Takayuki Nagai ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Polypoidal Choroidal Vasculopathy ◽  
Age Related Macular Degeneration ◽  
Morphological Parameters ◽  
Intravitreal Ranibizumab ◽  
Corrected Visual Acuity ◽  
Age Related ◽  
The Mean ◽  
Choroidal Vasculopathy

Purpose: To compare the response to ranibizumab between patients with typical neovascular age-related macular degeneration (tAMD) and those with polypoidal choroidal vasculopathy (PCV), and to determine the predictors for the outcomes. Methods: Fifty-nine eyes from 59 consecutive patients (tAMD: 27 eyes, PCV: 32 eyes) were treated with three monthly ranibizumab injections followed by as-needed retreatment. Best-corrected visual acuity (BCVA) and morphological parameters were evaluated over 24 months of follow-up. Results: The mean BCVA in tAMD and PCV patients was significantly improved at 3 months (-0.22 and -0.09 logMAR units, respectively). The improvement in BCVA was sustained up to 24 months in tAMD (p = 0.01) but not in PCV patients. The significant predictor for good response to ranibizumab in tAMD patients was the improvement of BCVA at 3 months, whereas that in PCV patients was the anatomical resolution at 3 months. Conclusions: Ranibizumab is an effective therapy for tAMD and PCV over 24 months. The predictors for good outcome might be different between tAMD and PCV.

CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE

Retina ◽  
2015 ◽  
Vol 35 (9) ◽  
pp. 1743-1749 ◽  
Author(s):  
Eric H. Souied ◽  
Hassiba Oubraham ◽  
Gérard Mimoun ◽  
Salomon Y. Cohen ◽  
Stéphane Quere ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Clinical Practice ◽  
Macular Degeneration ◽  
Daily Clinical Practice ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related

scholarly journals Clinical efficacy of aflibercept treatment in patients with ranibizumab-resistant neovascular age-related macular degeneration

2021 ◽  
Vol 14 (2) ◽  
pp. 97-104
Author(s):  
Victor V. Egorov ◽  
Galina P. Smoliakova ◽  
Lubov P. Danilova ◽  
Natalya S. Zhajvoronok ◽  
Yulia B. Solov'yeva ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Clinical Efficacy ◽  
Angiogenesis Inhibitor ◽  
Treatment Method ◽  
Age Related Macular Degeneration ◽  
Subretinal Space ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Additional Improvement

THE AIMwas to evaluate clinical efficacy of aflibercept treatment in patients with ranibizumab-resistant neovascular age-related macular degeneration. MATERIALS AND METHODS.13 patients (13 eyes) after intravitreal ranibizumab therapy for 1 year (from 6 to 8 injections with an interval of 1.5 to 2 months). However, in all patients, there was a recurrence of the exudative activity of the process.Aflibercept treatment method consisted of 3 monthly loading intravitreal injections with follow-up period of 4 months. RESULTS.One month after 1st aflibercept injection among all patients, the average index of best-corrected visual acuity (BCVA) increased to 0.410.02 and the central retinal thickness (CRT) index decreased to 30714.5 m versus the initial CRT value 43164 m. After the 3rd aflibercept injection, the CRT index was the lowest and amounted to 189.513.0 m, which was accompanied BCVA increase to 0.420.03 versus 0.290.05 as the initial value. According to the optical coherence tomography data, after loading phase, good anatomical effect was observed with significant edema reduction, complete resorption of fluid in the subretinal space, and decrease of the pigment epithelial detachments height. CONCLUSION.Evaluating the results of our study, we found that the use of angiogenesis inhibitor aflibercept made it possible to suppress the signs of activity of choroidal neovascularization and to obtain additional improvement of visual functions in patients with neovascular age-related macular degeneration, when the therapeutic effect from the early ranibizumab therapy was insufficient or completely absent.

scholarly journals Effect of Intravitreal Ranibizumab in the Treatment of Peripapillary Choroidal Neovascularisation

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Hassan Hamoudi ◽  
Torben Lykke Sørensen
Keyword(s):  
Macular Degeneration ◽  
Choroidal Neovascularisation ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Subfoveal Choroidal Neovascularisation ◽  
Age Related ◽  
The Mean ◽  
Receive Treatment ◽  
To Receive

Intravitreal ranibizumab therapy is widely used in treatment of subfoveal choroidal neovascularisation (CNV) in age-related macular degeneration. We wanted to study the effect of intravitreal ranibizumab therapy in peripapillary CNV. A prospective recording of treatment outcomes in twelve eyes (12 patients) with peripapillary CNV with intravitreal injections of ranibizumab was performed. The patients received a series of 3 injections 4–6 weeks apart, and then a new ophthalmic examination was made including OCT and further therapy was given if the peripapillary CNV was still active. Nine patients had idiopathic peripapillary CNV, and in 3 patients it was associated to age-related macular degeneration. Followup had to be at least 6 months. The mean follow-up time was 15.9 (range 9–27) months and the mean number of injections 6.2 (3–10). In 10 patients treatment had resulted in an inactivation of the peripapillary CNV, but 3 of them had reactivation, while 2 patients had no inactivation. Currently, 5 patients are continuous to receive treatment. VA improved in 10 patients. Intravitreal ranibizumab therapy appears to be effective in patients with peripapillary CNV, but in some cases there is repeated reactivation or continuous activity of the peripapillary CNV.

scholarly journals High frequency SD-OCT follow-up leading to up to biweekly intravitreal ranibizumab treatment in neovascular age-related macular degeneration

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Cengiz Tuerksever ◽  
Christian Pruente ◽  
Katja Hatz
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
High Frequency ◽  
Subretinal Fluid ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Age Related ◽  
Ranibizumab Treatment ◽  
Sd Oct

AbstractA remarkable proportion of neovascular age-related macular degeneration (nAMD) patients respond rather poorly to ranibizumab treatment, in spite of the minimum 4-week follow-up and treatment interval. Usually, retreatments are based on nAMD activity as evaluated by Spectral-domain Optical coherence Tomography (SD-OCT), biomicroscopic fundus examination and visual acuity changes. In this prospective pilot study, we aimed to study SD-OCT changes in a high-frequent follow-up manner (weekly (month 0–6), biweekly (month 7–12)) throughout the first year, which consequently led to intravitreal ranibizumab being administered up to biweekly. Best corrected visual acuity (BCVA) was already significantly improved at week 2. Central retinal thickness (CRT), intraretinal and subretinal fluid (SRF) were significantly improved from week 1 onwards. Half of the patients showed nAMD activity at week 2 or 3 and received the first retreatment earlier than 4 weeks after baseline injection. In total, 46% of retreatments were already applied 2 or 3 weeks after the previous treatment. Greater range of CRT and SRF fluctuation during follow-up was associated with lower final BCVA. Lower baseline BCVA and better SRF improvement at week 2 was associated with greater BCVA improvement. In conclusion, high-frequency SD-OCT follow-up provided a good option for adapting treatment in nAMD individually.

Sign in / Sign up

Export Citation Format

Share Document